Sep. 19, 2013, 12:05 PM
- Soligenix (SNGX.OB +11.2%) jumps after announcing it has received a contract from the Biomedical Advanced Research and Development Authority for the "preclinical and manufacturing development" of the GI ARS treatment OrbeShield.
- The initial deal is for two years and can be extended for up to five total years.
- The contract is valued at up to $26.3M and will help the company "successfully navigate and complete the FDA approval process." (PR)
SNGX vs. ETF Alternatives
We are a late-stage biopharmaceutical company developing product candidates intended to address unmet medical needs in areas of inflammation, oncology, and biodefense. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense. Our BioTherapeutics business segment is... More
Other News & PR